Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Researchers from the Universities of Cambridge, Bristol, and Edinburgh have revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of heart attacks and strokes.
剑桥大学、布里斯托大学和爱丁堡大学的研究人员透露，COVID-19疫苗可能会显著降低动脉血栓的发病率，这是心脏病发作和中风的主要原因。
The study, published in Nature Communications and supported by the British Heart Foundation Data Science Centre at Health Data Research U.K., analyzed de-identified health records of 46 million adults provided by NHS England.
这项研究发表于《自然·通讯》杂志上，并得到了英国心脏基金会数据科学中心和英国卫生数据研究机构提供的4600万成年人的匿名健康记录的支持。
Using health records from 45.7 million adults in England between December 2020 and January 2022, the study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second, and booster doses of brands and combinations of COVID-19 vaccines used during the U.K. vaccination program with the incidence before or without the corresponding vaccination.
利用英国2020年12月至2022年1月期间的4570万成年人健康记录，该研究比较了英国疫苗接种计划中使用的COVID-19疫苗品牌和组合的第一剂、第二剂和加强剂疫苗接种前或未接种时以及接种后至第26周的血栓和心血管并发症发病率。
The incidence of common arterial thrombotic events (mainly acute myocardial infarction or heart attack and ischaemic stroke) was generally lower after each vaccine dose, brand, and combination.
每种疫苗剂量、品牌和组合接种后，通常常见的动脉血栓事件（主要为急性心肌梗死或心脏病发作和缺血性卒中）发病率都较低。
There was a higher incidence of previously reported rare harms after vaccination, including:
接种后还出现了包括以下已经报道的罕见不良反应：
- Vaccine-induced thrombotic thrombocytopenia after the first AstraZeneca Plc's (NASDAQ:AZN) vaccine (ChAdOx1).
- Myocarditis and pericarditis (inflammation of the heart muscle and outer lining) after the first, second, and transiently after booster mRNA vaccination, including BioNTech SE (NASDAQ:BNTX) / Pfizer Inc (NYSE:PFE) BNT-162b2 and Moderna Inc's (NASDAQ:MRNA) vaccine, mRNA-1273.
- 在接种了阿斯利康股份有限公司（NASDAQ:AZN）的第一剂疫苗（ChAdOx1）后出现了疫苗相关性血栓性血小板减少症。
- 在接种mRNA疫苗，包括BioNTech SE (NASDAQ:BNTX) / 辉瑞公司（NYSE:PFE）的BNt-162b2和Moderna Inc（NASDAQ:MRNA）的mRNA-1273的第一、第二剂以及短暂的强化剂后，出现了心肌炎和心包炎（心脏肌肉和外层衬的炎症）。
For all vaccine brands and doses, adjusted hazard ratios (aHRs) were lower in the first few weeks than in later weeks. The aHR profiles for acute myocardial infarction and ischaemic stroke were similar to those of composite arterial thrombosis for all vaccine brands and doses.
对于所有疫苗品牌和剂量，调整过的风险比（aHRs）在最初几周比以后的几周要低。对于所有疫苗品牌和剂量，急性心肌梗死和缺血性卒中的aHR曲线与所有动脉血栓的组合相似。
Similarly, the incidence of common venous thrombotic events (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination.
同样，接种后常见的静脉血栓事件（主要为肺栓塞和下肢深静脉血栓）的发病率较低。
These findings support the wide uptake of future COVID-19 vaccination programs.
这些发现支持未来COVID-19疫苗接种计划的广泛推广。
In July, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an "excess of updated vaccines."
今年7月，阿斯利康因“更新的疫苗过多”而宣布了其COVID-19疫苗Vaxzevria的全球停产。
Earlier, Pfizer raised its 2024 guidance to $8.5 billion from $8 billion but reaffirmed that $5 billion would come from BioNTech's partnered Comirnaty-COVID-19 vaccine.
此前，辉瑞将其2024年的业绩预期从800亿美元提高至850亿美元，但重申500亿美元将来自BioNTech合作推出的Comirnaty-COVID-19疫苗。
Moderna also lowered its 2024 sales guidance on Thursday due to weaker demand for its COVID-19 vaccines.
Moderna也因其COVID-19疫苗的需求疲软而在周四下调了2024年的销售业绩指引。
- General Motors Plans Major Overhaul And Job Cuts In China: Report.
- 通用汽车计划在中国进行大规模改组和裁员：报告。
Photo via Wikimedia Commons
照片通过Wikimedia Commons